The predictive value of TNF-α and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes.
Some inflammation factors have been shown to accelerate type 2 diabetes macrovascular complication (T2DMC). The study investigates the variation of TNF-α and IL-6 levels during the progression of T2DMC to explore their predictive value in the incidence of T2DMC. All participants were divided into two groups, type 2 diabetes mellitus (T2DM) and non-diabetes (ND) group. TNF-α and IL-6 were analyzed with enzyme immunoassay. All participants were followed up by carotid Doppler, Doppler of lower extremities, head CT and 64-row multislice spiral CTA. The incidence of macrovascular atherosclerosis in T2DM was significantly higher than that in ND group (P < 0.05). The levels of TNF-α and IL-6 in both groups with atherosclerosis increased annually. In patients who had atherosclerosis with diabetes, measured levels of TNF-α and IL-6 were significantly higher than those in patients with atherosclerosis without diabetes (P < 0.05). The levels of TNF-α and IL-6 in T2DMC and ND group with atherosclerosis was significantly higher than that in two groups without atherosclerosis (P < 0.05). Patients with T2DM were divided into four groups according to their HbA1C level. There was a strong positive correlation between the levels of TNF-α and IL-6 and HbA1C (P > 0.05). The TNF-α and IL-6 levels can be used as predictors for atherosclerosis development. Compared with non-diabetic atherosclerosis, TNF-α and IL-6 have stronger predictive value in diabetic atherosclerosis development. One reason for hyperglycemia increasing atherosclerosis is to activate inflammatory cells and relives of inflammatory factors. Hyperglycemia can trigger inflammation, which is a quality-effect relationship reaction.
Wu
Weihua
W
Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, China. hui-90@163.com
Wang
Mingli
M
Sun
Zhenjie
Z
Wang
Xin
X
Miao
Jiajing
J
Zheng
Zhaohui
Z
D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology; D003925:Diabetic Angiopathies / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D015850:Interleukin-6 / Q000032:analysis / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000097:blood*
D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha